Emmaus 2025 net revenue $12.5M (-25% YoY); net loss widens to $7.2M

Emmaus Life Sciences, Inc.

Net revenue $12.5M vs $16.7M in 2024; net loss $7.2M ($0.11/sh) vs $6.5M ($0.10/sh).
Income from operations $0.2M, improved from operating loss of $1.9M; operating expenses fell 34% to $11.4M.
Cash and equivalents $2.1M at Dec 31, 2025, up from $1.4M at Dec 31, 2024.
Entered license/distribution deal with NeoImmuneTech for U.S. operations, expected Q2 2026.
Revenue drop driven by generic L-Glutamine competition in U.S., partially offset by MENA growth.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Emmaus Life Sciences, Inc. reported the year ended December 31, 2025 results: revenue $12.5 million, net income net loss of $7.2 million, or $0.11 per share, EPS $0.11 per share.

Period: the year ended December 31, 2025
Revenue: $12.5 million
Net income: net loss of $7.2 million, or $0.11 per share
EPS: $0.11 per share
Result: reported results

Exact text from the filing

Net revenues for the year ended December 31, 2025 were $12.5 million

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Emmaus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-036886

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.